GRN‑1: Grann Pharmaceuticals' mRNA‑LNP Therapeutic for Obesity & MASLD
26 Sep 2025
Oligonucleotide CMC & Process Development
- GRN‑1 leverages a lipid nanoparticle delivery system to deliver mRNA therapeutics targeting metabolic dysfunction‑associated steatotic liver disease (MASLD) and obesity
- In vivo studies with MS‑NASH mice showed GRN‑1 effectively reduced adipose tissue buildup and eliminated excess liver fat, even reversing liver cirrhosis in treated animals
- GRN‑1’s mechanism holds promise for treating a spectrum of related conditions—including alcoholic liver disease, metabolic syndromes, lysosomal storage disorders, and inflammation-driven adipose buildup
